SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-021835
Filing Date
2022-11-03
Accepted
2022-11-03 16:03:31
Documents
73
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-20220930.htm   iXBRL 10-Q 3727086
2 EX-31.1 ntla-ex31_1.htm EX-31.1 17522
3 EX-31.2 ntla-ex31_2.htm EX-31.2 17539
4 EX-32.1 ntla-ex32_1.htm EX-32.1 11190
  Complete submission text file 0000950170-22-021835.txt   13746369

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ntla-20220930_pre.xml EX-101.PRE 382271
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ntla-20220930.xsd EX-101.SCH 59457
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ntla-20220930_lab.xml EX-101.LAB 491082
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ntla-20220930_cal.xml EX-101.CAL 42887
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ntla-20220930_def.xml EX-101.DEF 248178
67 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20220930_htm.xml XML 3383002
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 221357855
SIC: 2835 In Vitro & In Vivo Diagnostic Substances